C WorldWide Group Holding A S Trims Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

C WorldWide Group Holding A S lowered its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 21.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 237,851 shares of the biotechnology company's stock after selling 66,000 shares during the period. C WorldWide Group Holding A S owned about 0.12% of BioMarin Pharmaceutical worth $16,814,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Jackson Creek Investment Advisors LLC acquired a new stake in BioMarin Pharmaceutical during the first quarter valued at approximately $948,000. Grandfield & Dodd LLC raised its stake in BioMarin Pharmaceutical by 7.6% during the first quarter. Grandfield & Dodd LLC now owns 18,712 shares of the biotechnology company's stock valued at $1,323,000 after buying an additional 1,320 shares in the last quarter. Parcion Private Wealth LLC acquired a new stake in BioMarin Pharmaceutical during the first quarter valued at approximately $332,000. Larson Financial Group LLC raised its stake in BioMarin Pharmaceutical by 515.8% during the first quarter. Larson Financial Group LLC now owns 2,266 shares of the biotechnology company's stock valued at $160,000 after buying an additional 1,898 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new stake in BioMarin Pharmaceutical during the first quarter valued at approximately $288,000. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Price Performance

Shares of BMRN traded down $0.18 during trading hours on Friday, hitting $58.20. 85,059 shares of the company were exchanged, compared to its average volume of 1,748,928. The company has a market capitalization of $11.16 billion, a PE ratio of 21.66, a PEG ratio of 0.81 and a beta of 0.17. The firm has a fifty day simple moving average of $57.24 and a 200-day simple moving average of $62.43. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.52 and a quick ratio of 3.49. BioMarin Pharmaceutical Inc. has a one year low of $52.93 and a one year high of $94.85.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer directly owned 14,173 shares in the company, valued at approximately $840,600.63. This trade represents a 11.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.85% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wall Street Zen upgraded BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. increased their price target on BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an "overweight" rating in a research report on Monday. The Goldman Sachs Group dropped their price target on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research report on Monday, May 5th. Wolfe Research set a $95.00 price target on BioMarin Pharmaceutical and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Morgan Stanley began coverage on BioMarin Pharmaceutical in a research report on Thursday, July 3rd. They set an "overweight" rating and a $97.00 price target on the stock. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $93.78.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.